At a glance
- Originator Taisho Pharmaceutical
- Class Growth factors; Neuroprotectants
- Mechanism of Action Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cerebral infarction
Most Recent Events
- 25 Jun 2001 No-Development-Reported for Cerebral infarction in Japan (Unknown route)
- 15 Oct 1997 Preclinical development for Cerebral infarction in Japan (Unknown route)